Mesothelioma trials

AI-generated summary

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma is being studied. Conditions: Mesothelioma, Thymoma, Pancreatic Neoplasms +2 • Eligibility: * INCLUSION CRITERIA: * All participants greater than or equal to 2 years of age with malignant mesothelioma. * All participants greater than or equal to18 years of…. Goal: Background: * Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothelioma accounts for 0.10% of deaths annually in the United States. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma is being studied. Conditions: Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant • Eligibility: Inclusion Criteria: * Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) after at least 1…. Goal: This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Verismo Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether a limited partial pleurectomy with decortication can help relieve symptoms in people with pleural mesothelioma that cannot be fully removed. It is for adults with epithelioid pleural mesothelioma affecting one side of the chest and classified as unresectable or borderline resectable after initial therapy. Researchers will look at symptoms, quality of life, complications after surgery, time to starting any additional treatment, and overall survival over about two years. Key exclusions include biphasic or sarcomatoid mesothelioma, cancer that has spread beyond the chest, progression during induction therapy, poor lung function, use of other investigational drugs, or uncontrolled illness.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests how cancers develop in people with inherited germline mutations in BAP1 or other cancer-predisposition genes, including mesothelioma patients and their family members. - It has two groups: Cohort 1 includes people with mesothelioma and a confirmed germline mutation; Cohort 2 includes people who carry a BAP1 mutation without mesothelioma or have relatives at risk. - Researchers will collect medical and family histories, do genetic testing, and follow participants with exams, imaging, possible tumor tissue testing, and regular follow-up by phone or visits to learn about cancer risk and disease patterns. - Eligibility requires age 2 or older for certain mutations, and there are no listed exclusions for genetic testing or surveillance.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NX-1607 in Adults With Advanced Malignancies is being studied. Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer +11 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received…. Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nurix Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests APG-115, an oral mdm2 inhibitor, in people with BAP1 Cancer Syndrome who also have early-stage mesothelioma. - It is for adults 18 and older who have a germline BAP1 mutation and subclinical/early-stage mesothelioma that does not yet require standard treatment. - The trial aims to determine whether APG-115 can stabilize or improve the disease, using pre- and post-treatment biopsies and imaging to assess response, with treatment given in 21-day cycles for up to 16 cycles. - The study is not yet recruiting. - Exclusions include cancers requiring frontline therapy, significant cardiovascular disease, certain drug interactions, active viral infections (HBV/HCV/HIV), pregnancy, and other unstable medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HTL0039732 is a new drug being tested in adults with advanced solid tumors, given alone or with atezolizumab or other approved cancer therapies. This is a first-in-human, early-phase study to find safe dose levels and to learn how the drug may affect tumors. In Phase 1 Part A, HTL0039732 is given as a monotherapy; in Phase 1 Part B it is given with atezolizumab, and Phase 2a will test the dose in specific cancer types where PGE2/EP4 signaling may be important. The study will also look at safety and potential side effects of HTL0039732 alone and in combination. Key exclusions include recent cancer therapies or immunotherapies, active autoimmune disease needing systemic treatment in the past 2 years, HIV or hepatitis B/C infection, pregnancy or breastfeeding, prior EP4 inhibitors, and receipt of live vaccines within 4 weeks before enrollment for parts involving immunotherapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests a combination of lenvatinib with pembrolizumab and chemotherapy for malignant pleural mesothelioma. - It is for adults with unresectable, advanced, or metastatic disease who have not had prior treatment for this cancer. - The trial aims to learn whether this drug combo is effective and safe, in a single-arm, open-label Phase II study. - Key exclusions include prior anti-PD-1/PD-L1 therapy, active autoimmune disease, active CNS metastases, pregnancy, and certain cardiovascular or infectious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests Tulmimetostat (DZR123/CPI-0209) as a single-drug therapy for advanced solid tumors and lymphomas, and also in combination with enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) in a later cohort. It starts with Phase 1 to find the safe dose (MTD/RP2D) and then moves to Phase 2 to assess safety, tolerability, and early anti-tumor activity across several disease-specific groups (including ARID1A-mutant endometrial/urothelial cancers and M7) and a combination cohort (M8). Participants are adults with various advanced cancers, with certain molecular subtypes and measurable disease, all with good performance status and organ function. Key exclusions include active brain metastases, significant cardiovascular disease, recent major surgery, uncontrolled infections, and prior EZH2 inhibitors; for the M8 cohort, prior enzalutamide or other AR pathway inhibitors may also exclude eligibility.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests a personalized treatment approach that uses a patient-derived tumor-like cell cluster (PTC) model to guide therapy for malignant peritoneal mesothelioma. - It is for adults 18 and older with epithelioid or biphasic MPM who are planned for cytoreductive surgery with heated chemotherapy (CRS+HIPEC) and can provide tumor tissue. - Participants are randomly assigned to either standard chemotherapy (gemcitabine, oxaliplatin, and apatinib) or a personalized plan where the PTC model tests drugs in the lab and selects the best one for the patient, with both groups receiving 6 cycles. - The study aims to see if PTC-guided treatment can help patients live longer without their cancer getting worse, compared with standard treatment, and it excludes people with another active cancer, severe medical conditions, or those unwilling to follow the treatment or follow-up.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT027 in Patients with Pleural Malignant Tumors is being studied. Conditions: Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma +3 • Eligibility: Inclusion Criteria: 1. voluntarily participate in the study and sign informed consent; 2. age over 18 years old (including the cut-off value), regardless of gender; 3. advanced malignant…. Goal: This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy.. Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Suzhou Maximum Bio-tech Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a combination of four drugs—sintilimab, bevacizumab, pemetrexed, and cisplatin—for adults with unresectable malignant peritoneal mesothelioma. - It is a single-arm study enrolling about 28 participants to evaluate how well the treatment works and how safe it is, and to explore biomarkers related to efficacy or safety. - Participants receive the four drugs every three weeks, with maintenance therapy after six cycles until disease progresses or side effects are unacceptable. - Eligibility includes adults (18+), ECOG 0-1, confirmed peritoneal mesothelioma, and ability to consent; key exclusions include active autoimmune disease, active infections, significant cardiovascular disease, pregnancy, and other factors that could interfere with the trial.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a first-in-human, open-label, dose-escalation study testing UCMYM802 injections (a circular mRNA CAR-T therapy targeting mesothelin) in mesothelin-positive advanced solid tumors to learn about safety, tolerability, how the body handles the treatment, immune responses, and early signs of anti-tumor activity. - It is for adults aged 18 to 70 with mesothelin-expressing advanced solid cancers who have failed or cannot tolerate standard treatments. - Participants will receive weekly injections for four weeks, with doses escalated from 1×10^8 to 2×10^9. - Key exclusions include active infections (HBV/HCV/HIV or syphilis), pregnancy, uncontrolled serious illness, prior anti-mesothelin or engineered cell therapy within 6 months, and known CNS metastases.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial is a pilot feasibility study testing a new multimodal treatment for unresectable malignant pleural mesothelioma, using intrapleural photodynamic therapy delivered during video-thoracoscopy, followed by nivolumab immunotherapy, in about 20 patients. It is for adults whose mesothelioma cannot be surgically removed and who have progressed after one or two lines of platinum-based chemotherapy, or who cannot have chemotherapy. The study aims to learn whether this combination can be delivered safely and feasibly, and to gather early information about its potential clinical benefit. Eligible participants are those with good performance status and measurable disease accessible for PDT, while key exclusions include pregnancy, prior anti-PD-1/PD-L1 treatment in the last five years, contraindications to 5-ALA/PDT or thoracoscopy, and significant organ dysfunction.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial is testing immune microenvironment and gene expression profiling in pleural and peritoneal mesothelioma to help classify patients and guide personalized treatment. It will collect tumor samples and analyze them with bulk gene expression, spatial transcriptome analysis, and 9-color multiplex immunofluorescence. The goal is to identify distinct PPM subgroups and potential actionable targets or pathways, which will be validated in patient-derived organoids or xenografts. About 220 patients are planned (150 retrospective, 70 prospective) across Italian centers; exclusions include inadequate tissue for analysis, patients not amenable to active oncologic treatment, and those lost to follow-up before 6 months after the end of treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study is being studied. Conditions: Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura, Neoadjuvant Chemoimmunotherapy • Eligibility: Inclusion Criteria: * Capable of written informed consent and adherence to study procedures * Pathologically confirmed PM (epithelioid), cT2-3 N0-1 M0 according to UICC TNM 9 and considered…. Goal: The goal of this clinical trial is to evaluate whether a combination of chemotherapy and immunotherapy can make surgery possible in adults with inoperable pleural mesothelioma (a type of cancer affecting the lung lining). The main questions it aims to answer are: Can two cycles of neoadjuvant chemotherapy and dual immunotherapy, followed by surgery, be completed safely and effectively? Phase/Status/Sponsor: Unknown phase; RECRUITING; University Hospital, Antwerp.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests adding elimusertib (BAY 1895344) to standard chemotherapy with cisplatin, or cisplatin plus gemcitabine, for adults with advanced solid tumors, including urothelial cancer. It is a dose-escalation phase I trial to find the safest and most effective dose and to learn how the combination behaves in the body. The trial will assess safety and tolerability, identify the maximum tolerated dose, and collect pharmacokinetics and early signs of activity, with a focus on urothelial cancer in the triplet arm. Eligible participants are adults 18 or older with measurable advanced disease for which cisplatin-based therapy is suitable; key exclusions include pregnancy, life expectancy under 6 weeks, uncontrolled illness, recent chemotherapy or radiotherapy, and certain drug interactions or prior ATR inhibitors. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors is being studied. Conditions: Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm +25 • Eligibility: Inclusion Criteria: * SCREENING: Patients with relapsed or refractory solid tumors and without known curative therapy or therapy proven to proven to prolong survival with acceptable quality of…. Goal: This phase I trial studies the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells (donor natural killer \[NK\] cells) and how well they work when given together with cyclophosphamide and etoposide in treating children and young adults with solid tumors that have come back (relapsed) or that do not respond to treatment (refractory). NK cells, white blood cells important to the immune system, are donated/collected from cord blood collected at birth from healthy babies and grown in the lab. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APG-2449 in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer +2 • Eligibility: Inclusion Criteria: 1. Dose exploration stage: non-small cell lung cancer diagnosed by histology and/or cytology and positive for ALK/ROS1 gene fusion (molecular diagnosis confirmed by the investigator) and…. Goal: APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. Phase/Status/Sponsor: Unknown phase; RECRUITING; Ascentage Pharma Group Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a new combination therapy for malignant mesothelioma: iparomlimab and tuvonralimab (QL1706) given with chemotherapy. - It is for adults with MM who are not candidates for radical surgery or radiotherapy and meet other health criteria. - The study has two phases: a small Phase Ib safety run-in, followed by a Phase II expansion to measure effectiveness in first-line and second-line patients. - Exclusions include prior CTLA-4 inhibitors, recent immune-modulating therapy, and significant cardiovascular disease in the past 6 months.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a patient’s own T cells that are genetically engineered to target mesothelin, given directly into the pleural space to treat malignant pleural disease. - It includes adults with MPD from mesothelioma, metastatic non-small cell lung cancer to the pleura, or breast cancer to the pleura who have already had at least one prior treatment and show mesothelin expression or elevated SMRP. - The study aims to find a safe dose and learn how these CAR T cells affect the cancer and the patient, with an initial dose‑escalation Phase I and a Phase II part that adds pembrolizumab for mesothelioma. - Key exclusions include active CNS metastases, certain autoimmune or cardiac conditions, active infections, pregnancy, and other health issues that could interfere with participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Exercise to Boost Immunity in Advanced Cancer is being studied. Conditions: Mesothelioma; Lung, Pancreatic Cancer • Eligibility: Inclusion Criteria: * Patients about to start or who are undergoing first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma or patients about to start or who…. Goal: The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Sheffield Teaching Hospitals NHS Foundation Trust.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests molecular analyses of blood, tumor tissue, normal tissue, and other body fluids to learn about cancer development, growth, and spread. - It is for adults with thoracic cancers: non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma, mesothelioma, or cancer of unknown primary presenting in the chest. - The goal is to identify markers that help diagnose cancer, predict outcomes, and predict response to targeted therapies, and to find targets for new treatments. - The project aims to create a registry of patients and tumors to better understand molecular changes in thoracic cancers and aid early detection. - Enrollment is by invitation, and participants must be able to give informed consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The ANTARES study is testing whether nivolumab, a PD-1 blocker, can work in people with advanced or metastatic rare tumors that express PD-L1 (CPS ≥ 10), regardless of tumor type. It is a phase II basket trial, enrolling adults whose cancers have higher PD-L1 expression after standard treatments have failed. Treatment can last up to 12 months, and researchers will look at objective responses, progression-free survival, and biomarkers like PD-L1, ctDNA, and microvesicles. Exclusions include prior immunotherapy, pregnancy or breastfeeding, active infection, autoimmune disease (with limited exceptions), and uncontrolled CNS metastases, among other health criteria.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors is being studied. Conditions: MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma +28 • Eligibility: Inclusion Criteria: 1. Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of PD1 mRNA high-expression…. Goal: This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; SOLTI Breast Cancer Research Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a short course of preoperative hemithoracic IMRT (radiation) given before surgery for malignant pleural mesothelioma (MPM). - It is for people with early-stage, resectable MPM who are candidates for extrapleural pneumonectomy, with eligibility including good performance status and adequate lung function. - The study aims to see if this preoperative radiation is feasible and safe and whether it can reduce tumor cell spread during surgery and lower the risk of metastasis, potentially improving survival. - If cancer is found in removed lymph nodes after surgery, patients may receive adjuvant chemotherapy; key exclusions include distant metastases, prior thoracic radiation or chemotherapy, serious non-malignant disease, or pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma is being studied. Conditions: Malignant Pleural Mesothelioma • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Karnofsky performance status \> 70% * Pathologic diagnosis of malignant pleural mesothelioma. * Potentially resectable by pleurectomy/decortication, as assessed by…. Goal: This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase 1/2 trial testing TC-510, a novel autologous engineered T cell therapy, in adults with advanced cancers that express mesothelin. TC-510 uses T cells modified with a mesothelin-targeting single-domain antibody fused to CD3 and a PD-1:CD28 switch receptor to boost activity against PD-L1–positive cancer cells. Eligible cancers include malignant pleural mesothelioma, serous ovarian adenocarcinoma, pancreatic adenocarcinoma, triple-negative breast cancer, and colorectal cancer, as long as the tumor shows mesothelin expression by immunohistochemistry. Participants must be 18 or older, have 1–5 prior systemic therapies for metastatic or unresectable disease, a good performance status (ECOG 0–1), be fit for leukapheresis, and have adequate organ function; key exclusions are inability to follow study procedures and known non-compliance or drug/alcohol use.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests NGM438 as a standalone treatment and in combination with pembrolizumab for advanced or metastatic solid tumors, to learn about safety and potential effectiveness. It targets adults whose cancer has progressed after other therapies or who could not tolerate them. Eligible participants need adequate bone marrow, kidney, and liver function and a performance status of 0 or 1. They must have recovered from prior treatment side effects to baseline or to CTCAE Grade 1. A key exclusion is prior treatment targeting LAIR1.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) is being studied. Conditions: Peritoneum Cancer, Peritoneum Neoplasm, Pleural Cancer +12 • Eligibility: Inclusion criteria: * verified peritoneal metastasis * colorectal cancer * ovarian cancer * gastric cancer * appendical cancer * pseudomyxoma peritonei * malignant mesothelioma * pancreatic cancer *…. Goal: Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases. Indication is decided by the treating physician. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Sabine Rhode.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma +2 • Eligibility: Key Inclusion Criteria: 1. Age ≥18 years. 2. Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, and malignant pleural mesothelioma. 3.…. Goal: This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; CRISPR Therapeutics AG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tazemetostat Expanded Access Program for Adults With Solid Tumors is being studied. Conditions: Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma +17 • Eligibility: Inclusion Criteria: 1. Age (at the time of consent): \>18 years of age. 2. They are unable to participate in tazemetostat clinical trials for their condition. 3. Can…. Goal: Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Phase/Status/Sponsor: Unknown phase; NO_LONGER_AVAILABLE; Epizyme, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors is being studied. Conditions: Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST) +9 • Eligibility: Inclusion Criteria: 1. Voluntarily signed and dated written informed consent prior to any specific-study procedure. 2. Age ≥ 18 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status…. Goal: Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage. Phase/Status/Sponsor: Unknown phase; COMPLETED; PharmaMar.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tested niraparib, a PARP inhibitor, in adults whose tumors have BAP1 or other DNA damage repair (DDR) gene mutations. - It was open-label and non-randomized, sponsored by the University of Florida, to see if niraparib can shrink DDR-deficient cancers. - Eligible participants included adults with incurable cancers such as uveal melanoma, mesothelioma, clear cell renal cell carcinoma, or cholangiocarcinoma (cohort A) with a confirmed DDR mutation (with a separate cohort for additional DDR criteria). - Exclusions included prior PARP inhibitor therapy and known BRCA1/2 mutations; the trial has been completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion is being studied. Conditions: Malignant Pleural Effusion, Lung Cancer, Mesothelioma +2 • Eligibility: Inclusion Criteria: * Patients must have MPE (defined as positive pleural fluid cytology). Eligible patients include NSCLC, small cell lung cancer, malignant mesothelioma (MM), breast cancer and ovarian…. Goal: This is a phase I study of intrapleural AdV-tk therapy in patients with malignant pleural effusion (MPE). The primary objective is to test the safety of intrapleural AdV-tk therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Candel Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Diadem to Investigate the Activity and Safety of Durvalumab is being studied. Conditions: Pleura Mesothelioma • Eligibility: Inclusion Criteria: 1. Histological diagnosis of advanced unresectable MPM; 2. Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (preferred) or at least 5 unstained slides for central…. Goal: Malignant pleural mesothelioma (MPM) is a cancer with high mortality rate and few therapeutic options.essentially all patients usually progress and die subsequently to a first line therapyl. There is strong evidence that the immune system is deeply involved in the biogenesis of MPM and that an imbalance in pro-inflammatory cytokines and exhausted adaptive T-cell mediated immune response are the main causes of neoangiogenesis, progression and metastatisation processes.Numerous Phase II-III clinical trials are underway evaluating Durvalumab either as monotherapy or combination with evidence of activity in a wide range of solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Mario Negri Institute for Pharmacological Research.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) is being studied. Conditions: Malignant Pleural Mesothelioma, Solid Tumors • Eligibility: Inclusion Criteria: 1. Signed informed consent obtained prior to initiation of any study-specific procedures 2. Phase I: Histologically confirmed solid malignancy that is metastatic or unresectable and for…. Goal: The phase I part of the study is a dose-finding study of escalating doses of CBP501 combined with full-dose cisplatin and pemetrexed in patients with histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or would otherwise be eligible for cisplatin and pemetrexed as first-line therapy. The maximum tolerated dose (MTD) will be determined based on DLTs occurring during the first treatment cycle. Phase/Status/Sponsor: Unknown phase; COMPLETED; CanBas Co. Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin is being studied. Conditions: Malignant Pleural Mesothelioma, Nonsquamous Nonsmall Cell Neoplasm of Lung • Eligibility: Inclusion Criteria: 1. Patients must be diagnosed with MPM or non squamous NSCLC. 2. Inoperable disease according to local surgeon, not previously treated with chemotherapy; patients relapsed/progressed after…. Goal: This is a prospective, open-label, mono-centric, phase I-Ib trial of Tivantinib in combination with Pemetrexed and Carboplatin as first-line therapy in patients with advanced or metastatic cancer suitable for a Carboplatin and Pemetrexed regimen as part of their specific therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Armando Santoro, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials is being studied. Conditions: Lymphoma, Mesothelioma, Prostate Cancer +1 • Eligibility: * INCLUSION CRITERIA: This study is open to all people with or who have been treated for cancer at the NIH CC in Bethesda, Maryland and meet the…. Goal: Background: A cancer diagnosis is a threat to life and bodily integrity. This can cause people with cancer to experience traumatic stress. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Phase I trial tests an intrapleural gene therapy called BG00001, which delivers the interferon-beta gene into the pleural space to treat malignant pleural mesothelioma or malignant pleural effusions. It is for adults 18 and older whose disease has progressed after standard therapy and whose pleural space can be accessed with a chest catheter. The study aims to find a safe dose, determine the maximum tolerated dose, assess gene transfer and interferon-beta expression, monitor immune responses, and look for early signs of tumor effect. Key exclusions include HIV positivity, active brain metastases (unless previously treated with no active growth), ongoing immunosuppressive therapy, pregnancy, and other active cancers within the past 5 years (with limited exceptions for certain skin cancers or successfully treated localized bladder or prostate cancer).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma is being studied. Conditions: Pleural Malignant Mesothelioma • Eligibility: Inclusion Criteria: * Pathologically \[histologically or cytologically\] documented pleural malignant mesothelioma. Patients must have had at least one, but no more than two prior systemic therapies, at least…. Goal: This study is being conducted to evaluate the overall safety and effectiveness of an investigational drug, GC1008, in patients with mesothelioma. An investigational drug is one that has not been approved by the FDA. Phase/Status/Sponsor: Unknown phase; COMPLETED; Abramson Cancer Center at Penn Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chest Wall Motion Analysis in Disease is being studied. Conditions: Mesothelioma, Lung Neoplasms, Surgery +5 • Eligibility: Inclusion Criteria: * Aged 16 or over * Have thoracic disease or healthy control Exclusion Criteria: * Unable to provide valid informed consent. Goal: Breathing movements, called chest wall motion, are very complex. The investigators are studying how movement of the abdomen, ribs and diaphragm contribute to breathing and how this differs with different diseases in the chest. Phase/Status/Sponsor: Unknown phase; COMPLETED; Heart of England NHS Trust.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * Male or female, ≥ 18 years of age. * Diagnosis of cancer. * Opioid-tolerant. Subjects who were opioid tolerant were those taking ≥ 60 mg…. Goal: This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Phase/Status/Sponsor: Unknown phase; COMPLETED; INSYS Therapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors is being studied. Conditions: Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer +4 • Eligibility: DISEASE CHARACTERISTICS: * Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer with clinical, radiological, or histologic evidence of incurability * Patients with thyroid…. Goal: RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Ottawa Regional Cancer Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Interleukin-12 in Treating Patients With Cancer in the Abdomen is being studied. Conditions: Anal Cancer, Colorectal Cancer, Gallbladder Cancer +2 • Eligibility: DISEASE CHARACTERISTICS: Histologically or cytologically confirmed Mullerian carcinoma (ovarian epithelial or peritoneal carcinoma) (closed to accrual as of 8/23/01) OR Gastrointestinal cancer with abdominal carcinomatosis OR Peritoneal mesothelioma…. Goal: RATIONALE: Interleukin-12 may kill tumor cells by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients with cancer in the abdomen. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists * Brain metastases allowed provided both…. Goal: RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Advanced solid tumor for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit, or they must be ineligible…. Goal: This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion. Phase/Status/Sponsor: Unknown phase; TERMINATED; Actym Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding early palliative care to standard oncology care improves quality of life for adults with incurable, advanced lung cancer or non-colorectal GI cancers, compared with standard care alone. - Participants are adults (18+) with confirmed advanced disease not being treated curatively, who were told their disease is incurable within the past 8 weeks, and who are under an oncologist’s care at participating outpatient centers with English reading ability. - Family caregivers who regularly accompany the patient to most visits and have in-person contact at least twice per week can participate. - The main goal is to measure patient-reported quality of life at 12 weeks; secondary goals include other patient and caregiver outcomes and end-of-life care/resource use, plus agreement between patient and caregiver views on prognosis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent is being studied. Conditions: Recurrent Pleural Malignant Mesothelioma, Stage IV Pleural Mesothelioma • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed diagnosis of unresectable malignant pleural mesothelioma * Patients must have measurable or non-measurable disease documented by computed tomography (CT) scan;…. Goal: This phase II trial studies how well nintedanib works in treating patients with malignant pleural mesothelioma that has come back. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; Barbara Ann Karmanos Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies is being studied. Conditions: Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis • Eligibility: Inclusion Criteria: * Patients with histologically confirmed peritoneal surface malignancies, including but not limited to malignant peritoneal mesothelioma and peritoneal carcinomatosis (PC) from presumed appendiceal and colorectal primary…. Goal: This trial is to determine the safest dose of a triple combination (chemokine modulatory regimen or CKM) of celecoxib, interferon alfa (IFN), and rintatolimod that can be given with a DC vaccine as treatment of peritoneal surface malignancies after standard of care surgery. The first phase of this study will determine the safest dose of IFN that can be given in combination with celecoxib and rintatolimod along with a DC vaccine. Phase/Status/Sponsor: Unknown phase; COMPLETED; David Bartlett.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tested INCB099280 to see if it is safe and tolerable, how the drug behaves in the body, and whether there is any early anti-tumor activity. It was for adults with advanced solid tumors that cannot be cured with surgery or standard treatments and that have measurable disease. The study aimed to learn about safety, pharmacokinetics, pharmacodynamics, and any early clinical benefit of the drug. Key exclusions included active infections, significant heart disease, untreated or progressing brain metastases, HIV or hepatitis B/C, prior anti-PD-L1 therapy, and recent systemic anticancer treatments.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors is being studied. Conditions: Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma +6 • Eligibility: Key Inclusion Criteria: * Have a histologically or pathologically documented, locally-advanced or metastatic solid tumor for which standard curative measures do not exist or are no longer effective…. Goal: To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01). Phase/Status/Sponsor: Unknown phase; TERMINATED; Turnstone Biologics, Corp..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S is being studied. Conditions: Astrocytoma, Brain Cancer, Brain Metastases +20 • Eligibility: Inclusion Criteria: 1. Male or female participants aged ≥18 years at the time of informed consent. 2. Adequate Bone Marrow Function 3. Adequate renal function 4. Adequate Liver…. Goal: This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression. The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Quadriga Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vinorelbine in Mesothelioma is being studied. Conditions: Mesothelioma • Eligibility: Inclusion Criteria: 1. Confirmed histological diagnosis of malignant pleural mesothelioma. The same block or 10 unstained slides should be available for translational research 2. Prior treatment with first-line…. Goal: This study is for patients with malignant mesothelioma of the lung lining (called pleura) who have had previous chemotherapy with a platinum-based regimen whose disease has progressed. Malignant pleural mesothelioma (MPM) is an aggressive, frequently drug resistant, and incurable disease that is increasing in incidence in the UK and worldwide. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wales Cancer Trials Unit.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- Researchers studied BAP1 gene changes in patients with mesothelioma, choroidal nevus, primary uveal melanoma, or metastatic uveal melanoma, looking for both somatic (tumor) and germline (inherited) mutations. - The participants were patients seen at Memorial Sloan Kettering Cancer Center. - The goal was to determine how common BAP1 mutations are in these diseases. - There were no listed exclusion criteria. - The study status is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers is being studied. Conditions: Solid Organ Cancers • Eligibility: Inclusion Criteria: * Histologically-proven diagnosis of advanced (AJCC, 7th Edition: stage III or IV) or aggressive solid organ cancer. * Patients must provide written consent for a core…. Goal: The purpose of this study is to evaluate the safety of the investigational product GL-ONC1. GL-ONC1, a vaccinia virus, has been genetically modified for use as a potential anti-cancer drug to destroy cancer cells. Phase/Status/Sponsor: Unknown phase; TERMINATED; Andrew Lowy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Rapamycin With Grapefruit Juice for Advanced Malignancies is being studied. Conditions: Tumors, Neoplasm Metastasis • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. *…. Goal: The purpose of this study is to determine the highest safe dose of rapamycin when given with a fixed amount of grapefruit juice. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma is being studied. Conditions: Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary +1 • Eligibility: Inclusion Criteria: * Be able to undergo peripheral blood leukapheresis; have successful placement of an intraperitoneal catheter * Be diagnosed with one of the following: metastatic or unresectable…. Goal: This is a phase 1 dose escalation study to characterize the feasibility, safety and tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly doses for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, and subjects with peritoneal mesothelioma with recurrence after prior chemotherapy. The study will also assess multiple cycles of treatment and adding preconditioning with cyclophosphamide. Phase/Status/Sponsor: Unknown phase; TERMINATED; MaxCyte, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tested an imaging agent called 89Zr-girentuximab to detect CAIX expression in solid tumors using PET/CT. - It was for adults 18 and older with a proven solid tumor, including cancers such as cervical, colorectal, esophageal, gastric, brain tumors (GBM), head and neck cancers, lung cancers, ovarian cancer, pancreatic cancer, soft tissue sarcoma, mesothelioma, and certain VHL-related lesions. - Researchers aimed to learn how well this PET imaging can identify CAIX on tumors and what it reveals about CAIX expression across cancer types. - Key exclusions included recent radionuclide exposure, prior CAIX-targeting treatments, pregnancy, significant kidney impairment (GFR ≤45), and other major illnesses or allergy to the imaging agents. - Status: terminated.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers is being studied. Conditions: Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma +5 • Eligibility: Inclusion Criteria: 1. Signed and dated PICF obtained prior to any trial-specific procedure that is not part of standard patient care. 2. Patient is ≥ 18 years-old at…. Goal: REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with select advance, previously treated, Mismatch Repair-Proficient/Microsatellite (pMMR/MSS) stable solid cancers. The multi-cohort design will allow for the examination of 8 separate cohorts of different cancers to determine whether further examination may be warranted in the individual indications. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Translational Research in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.